Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

ADRB2 genotype-guided treatment for childhood asthma: Cost analysis of the PUFFIN and PACT trials.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology·2025

Same author

Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study.

BMC cancer·2021

Same author

[The rise, fall, and possible rise of LSD].

Tijdschrift voor psychiatrie·2020

Same author

[Detection and treatment of familial hypercholesterolaemia; the earlier, the better?]

Nederlands tijdschrift voor geneeskunde·2020

Same author

Effects of short-term exposures to ultrafine particles near an airport in healthy subjects.

Environment international·2020

Same author

Recent developments in genetics and medically-assisted reproduction: from research to clinical applications<sup>†‡</sup>.

Human reproduction open·2019

Search research articles

Related Experiment Video

Updated: Jun 15, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

Ethical and social issues in pharmacogenomics testing.

S J H Vijverberg¹, T Pieters, M C Cornel

¹Department of Clinical Genetics/EMGO Institute, BS7, D423, VU University Medical Center, PO Box 7057, NL-1007 MB Amsterdam, The Netherlands.

Current Pharmaceutical Design

|March 9, 2010

Summary

This summary is machine-generated.

Pharmacogenomics research rapidly advances, presenting ethical challenges in data privacy and clinical application. Balancing innovation with patient protection and evidence-based translation is crucial for responsible genomic medicine.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Related Experiment Videos

Last Updated: Jun 15, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Area of Science:

Genomics and Precision Medicine
Bioethics
Translational Research

Background:

Genomics research is rapidly identifying disease pathways and drug roles.
Ethical considerations in research evolve with the pace of discovery.
Genomic information privacy is increasingly challenging.

Purpose of the Study:

Discuss ethical and social challenges in pharmacogenomics research and clinical applications.
Explore the need for new balances in privacy and data protection.
Address the translation gap for clinical pharmacogenomics.

Main Methods:

Review of ethical and social challenges in pharmacogenomics.
Analysis of clinical applications and translational research barriers.
Discussion of direct-to-consumer testing implications.

Main Results:

Genomic research, especially genome-wide association studies, requires international collaboration and raises privacy concerns.
Clinical translation of pharmacogenomics faces delays, necessitating evidence assessment.
Direct-to-consumer genetic testing is rapidly advancing, outpacing clinical integration.

Conclusions:

A new ethical balance is needed for genomic research, emphasizing veracity and protection against discrimination.
Translational research and evidence assessment are vital for safe clinical implementation of pharmacogenomics.
International quality standards are required for both clinical pharmacogenomics and direct-to-consumer testing.